PMID- 22222578
OWN - NLM
STAT- MEDLINE
DCOM- 20120514
LR  - 20120116
IS  - 1537-4505 (Electronic)
IS  - 1531-7129 (Linking)
VI  - 33
IP  - 2
DP  - 2012 Feb
TI  - MICA-STR A.4 is associated with slower hearing loss progression in patients with 
      Meniere's disease.
PG  - 223-9
LID - 10.1097/MAO.0b013e31824296c8 [doi]
AB  - HYPOTHESIS: Immune response may influence hearing outcome in Meniere's disease 
      (MD). BACKGROUND: Major histocompatibility complex class I chain-related A (MICA) 
      encodes a highly polymorphic stress-inducible protein, which interacts with NKGD2 
      receptor on the surface of NK, gammadelta T cells and T CD8 lymphocytes. We investigated 
      the association of MICA gene with hearing outcome in MD and its linkage 
      disequilibrium (LD) with human leukocyte antigen (HLA)-B. METHODS: MICA short 
      tandem repeat polymorphism (MICA-STR) was genotyped using a polymerase chain 
      reaction-based method in a total of 302 Spanish patients with MD and 420 healthy 
      controls. Genotyping of HLA-B was performed using polymerase chain reaction and 
      detected with reverse sequence-specific oligonucleotide probe system in 292 
      patients and 1,014 controls. RESULTS: Hearing loss was associated with the 
      duration of MD (p = 0.001). We found that MICA*A5 alelle was significantly 
      associated in the Mediterranean set (Pc = 0.04, odds ratio = 0.51 [95% confidence 
      interval, 0.30-0.84]), but this finding was not replicated in the Galicia 
      population. However, median time to develop hearing loss greater than 40 dB was 
      16 years (95% confidence interval, 9-23) for patients with the MICA*A.4 allele 
      and 10 years (95% confidence interval, 9-11) for patients with another MICA-STR 
      allele (log-rank test, p = 0.0038). We did not find statistical differences in 
      the distribution of B locus between the MD and the control group. In the LD 
      analysis, MICA*A5.1-HLA-B*07 (8.8%), MICA*A6-HLA-B*44 (8.3%), and 
      MICA*A6-HLA-B*51 (8.3%) were the most common haplotypes, and the stronger LD was 
      found for haplotypes MICA*A.4-HLA-B*18 (r2 = 0.41) and MICA*A.4-HLA-B*27(r2 = 
      0.29). CONCLUSION: The allelic variant MICA*A.4 is significantly associated with 
      slower progression of hearing loss in patients with MD. This suggests that the 
      immune response influence hearing level in MD.
FAU - Gazquez, Irene
AU  - Gazquez I
AD  - Otology and Neurotology Group CTS495, GENYO, Centro de Genomica e Investigacion 
      Oncologica-Pfizer/Universidad de Granada/Junta de Andalucia, Granada, Spain.
FAU - Moreno, Antonia
AU  - Moreno A
FAU - Aran, Ismael
AU  - Aran I
FAU - Soto-Varela, Andres
AU  - Soto-Varela A
FAU - Santos, Sofia
AU  - Santos S
FAU - Perez-Garrigues, Herminio
AU  - Perez-Garrigues H
FAU - Lopez-Nevot, Alicia
AU  - Lopez-Nevot A
FAU - Requena, Teresa
AU  - Requena T
FAU - Lopez-Nevot, Miguel Angel
AU  - Lopez-Nevot MA
FAU - Lopez-Escamez, Jose Antonio
AU  - Lopez-Escamez JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Otol Neurotol
JT  - Otology & neurotology : official publication of the American Otological Society, 
      American Neurotology Society [and] European Academy of Otology and Neurotology
JID - 100961504
RN  - 0 (DNA Primers)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (MHC class I-related chain A)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Child
MH  - DNA/genetics
MH  - DNA Primers
MH  - Disease Progression
MH  - Exons/genetics
MH  - Female
MH  - Genetic Association Studies
MH  - Genotype
MH  - HLA Antigens/genetics
MH  - Hearing Loss/epidemiology/*etiology/*genetics
MH  - Heterozygote
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Linkage Disequilibrium
MH  - Male
MH  - Meniere Disease/*complications/epidemiology/*genetics
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Recurrence
MH  - Spain/epidemiology
MH  - Survival Analysis
MH  - Young Adult
EDAT- 2012/01/10 06:00
MHDA- 2012/05/15 06:00
CRDT- 2012/01/07 06:00
PHST- 2012/01/07 06:00 [entrez]
PHST- 2012/01/10 06:00 [pubmed]
PHST- 2012/05/15 06:00 [medline]
AID - 10.1097/MAO.0b013e31824296c8 [doi]
PST - ppublish
SO  - Otol Neurotol. 2012 Feb;33(2):223-9. doi: 10.1097/MAO.0b013e31824296c8.